GlobeNewswire

XBiotech Announces Dismissal of Securities Class Action Suit

Del

AUSTIN, Texas, Oct. 24, 2018 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today that the honorable Judge Dustin M. Howell of the 459th Travis County District Court has issued a letter ruling granting the Company’s Motion to Dismiss the securities class action complaint brought against XBiotech (Case D-1-GN-17-003063). The District Court has directed the parties to prepare a formal order memorializing the ruling.

“These types of securities class action cases have unfortunately proliferated against development-stage biosciences companies. We are gratified that the District Court made the right call in this case and hope that other courts will take a similar approach in future securities class action cases against the biosciences industry,” stated Peter Stokes, Esq., Partner at Norton Rose Fulbright and XBiotech’s lead counsel in the case.

John Simard, President & CEO of XBiotech, commented, “This case was the last remaining frivolous lawsuit or lawsuit of any kind pending against XBiotech.  We had faith in the system, and in our superb legal counsel, and refused to settle with any other outcome than outright dismissal. Despite obstacles, our endeavor to discover, manufacture, and develop therapies derived from natural human immunity has continued unabated. We now have promising initiatives in infectious disease, dermatology, cardiovascular medicine, and cancer. The potential is extraordinary. I believe the tide is turning and I am more excited than ever about the future of XBiotech.”

On December 1, 2015, a purported securities complaint was filed against the Company, certain of its officers and directors and the underwriter for its initial public offering in the Superior Court for the State of California, Los Angeles County. At a June 2017 hearing before the Superior Court for the State of California, Los Angeles County, the judge ruled that the case belonged in Texas, not in California.  The plaintiffs re-filed their suit in Travis County District Court in July 2017. The county court ultimately heard arguments on XBiotech’s motion to dismiss and issued the letter ruling granting the dismissal. Two federal cases were previously filed in the U.S. District Court for the Western District of Texas, but both of those cases have also been dismissed.

About True Human™ Therapeutic Antibodies
XBiotech’s True Human™ antibodies are derived without modification from individuals who possess natural immunity to certain diseases. With discovery and clinical programs across multiple disease areas, XBiotech’s True Human antibodies have the potential to harness the body’s natural immunity to fight disease with increased safety, efficacy and tolerability.

About XBiotech
XBiotech is a fully integrated global biosciences company dedicated to pioneering the discovery, development and commercialization of therapeutic antibodies based on its True Human™ proprietary technology. XBiotech currently is advancing a robust pipeline of antibody therapies to redefine the standards of care in oncology, inflammatory conditions and infectious diseases. Headquartered in Austin, Texas, XBiotech also is leading the development of innovative biotech manufacturing technologies designed to more rapidly, cost-effectively and flexibly produce new therapies urgently needed by patients worldwide. For more information, visit www.xbiotech.com.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements, including declarations regarding management's beliefs and expectations that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "would," "could," "expects," "plans," "contemplate," "anticipates," "believes," "estimates," "predicts," "projects," "intend" or "continue" or the negative of such terms or other comparable terminology, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to inherent risks and uncertainties in predicting future results and conditions that could cause the actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties are subject to the disclosures set forth in the "Risk Factors" section of certain of our SEC filings. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Contact
Ashley Otero
aotero@xbiotech.com
512-386-2930

Om GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

Abeona Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results18.3.2019 21:45:00 CETPressemelding

On track to initiate Phase 3 VITAL™ trial for treatment of RDEB in mid-2019; EB-101 to be manufactured in-house Manufacturing scaled to support AAV based programs; GMP readiness expected 2H19 Investor conference call on Tuesday, March 19 at 10:00 a.m. ET NEW YORK and CLEVELAND, March 18, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company developing novel cell and gene therapies for serious diseases, today announced fourth quarter and full year 2018 financial results, and provided business highlights. The Company will host a conference call on Tuesday, March 19 at 10:00 a.m. ET to discuss fourth quarter and full year results, and to provide business highlights. Interested parties are invited to participate in the call by dialing 844-369-8770 (toll-free domestic) or 862-298-0840 (International) or via webcast at https://www.investornetwork.com/event/presentation/44847. “The diligent work conducted over the past nine months

Novavax Reports Fourth Quarter and Year-End 2018 Financial Results18.3.2019 21:05:00 CETPressemelding

Company to Host Conference Call Today at 4:30 p.m. ET GAITHERSBURG, Md., March 18, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the fourth quarter and twelve months ended December 31, 2018. “In 2018, we committed to focus on our two lead programs, ResVax™ and Nanoflu™, and reflecting on last year’s activities, I am proud to say we have achieved significant results for both,” said Stanley C. Erck, President and CEO of Novavax, Inc. “Although we were disappointed to miss the primary endpoint of our Prepare trial, ResVax is the first RSV vaccine to demonstrate efficacy for the prevention of RSV disease in a Phase 3 clinical trial. In addition, the successful Phase 2 results for our NanoFlu vaccine provide an opportunity to now confirm with the FDA the use of accelerated approval for licensure. We are now prepared to make meaningful advances on these programs during 2019.” Fourth Quarter 2018 and Subsequent Opera

Mattson Technology Announces Hydrilis™, a Unique High-Productivity Vacuum Wafer Process Platform18.3.2019 17:00:00 CETPressemelding

– Up to 4 process chambers and 8 wafer processing stations – – Smallest footprint, highest throughput platform – – Enables any process chamber, any position configuration flexibility – FREMONT, Calif., March 18, 2019 (GLOBE NEWSWIRE) -- Mattson Technology, Inc., a leading supplier of advanced process equipment used to manufacture semiconductors, introduces Hydrilis™, the industry’s highest productivity density vacuum transfer platform featuring high throughput on the smallest footprint. The Hydrilis platform can be configured with up to 4 process chambers, or 8 processing stations, for parallel or sequential wafer processing. Any of the paradigmE® family plasma etch process chambers, Suprema® family plasma photoresist strip and hard-mask removal process chambers, Novyka™ family surface treatment process chambers and Novyka family selective chemical dry etch process chambers can all be integrated on the Hydrilis platform. “Throughput per unit area of fab space is one of the key criteria

Minerva Neurosciences to Host Webcast Event on Schizophrenia18.3.2019 13:30:00 CETPressemelding

Decision Resources Group to provide review of the disease landscape and forecast Key opinion leader to discuss negative symptoms in schizophrenia Minerva to outline roluperidone’s potential position within the disease landscape WALTHAM, Mass., March 18, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will host a webcast, “Schizophrenia: Disease Landscape and Forecast,” on Thursday, March 21, 2019 beginning at 10:00 a.m. eastern time in Boston, MA. Minerva’s Executive Chairman and Chief Executive Officer, Remy Luthringer, Ph.D., will be joined by representatives from Decision Resources Group, a global information and technology services company providing proprietary data and solutions to the healthcare industry, and Dr. Gregory Strauss, an expert key opinion leader. Discussions will feature the following speakers

Infovista Enhances Ipanema SD-WAN with Nextgen Application Intelligence+ and Cloud-Native Orchestration18.3.2019 13:00:00 CETPressemelding

PARIS and ASHBURN, Va., March 18, 2019 (GLOBE NEWSWIRE) -- Infovista, the leader in modern network performance, today announced new cloud-native management and control with next-generation Application Intelligence+ for Ipanema SD-WAN, delivering unmatched application performance across any WAN. Tweet This: Infovista enhances Ipanema SD-WAN with nextgen Application Intelligence+ and cloud native orchestration: https://bit.ly/2ULcKLW #SmarterSDWAN The enterprise network has become the central nervous system of modern digital businesses, and SD-WAN is enabling this digital transformation. Infovista’s Ipanema SD-WAN with new cloud-native management and control of applications tightly combines session-based routing and dynamic path selection of the underlay network with an overlay of deep application visibility and dynamic control of the quality of experience for business-critical applications. Additionally, Ipanema automatically understands application delivery requirements and maintains a

Inspirata and Ohio State University Continue to Break Digital Pathology Barriers18.3.2019 12:30:00 CETPressemelding

Columbus, Ohio Columbus, Ohio, March 18, 2019 (GLOBE NEWSWIRE) -- Less than one year ago Inspirata announced that their digital pathology solution was used to make the first-ever primary digital diagnosis in the U.S., initiating a new era in cancer diagnostics. Today, cancer informatics and digital pathology workflow solution provider Inspirata®, Inc. announced the company with the help of The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute (OSUCCC-James) has broken another barrier- Inspirata and the OSUCCC – James have scanned over one-million anatomic pathology slides into high resolution whole slide digital images. “This historic accomplishment has demonstrated that it is possible to create large repositories of diagnostic quality prospective and retrospective slides creating imaging data that will accelerate clinical and research efforts,” says Inspirata Scan Center Manager, Trina Shanks, MLT (ACSP), CPC. Inspirata will presen